Noninvasive diagnosis of nonalcoholic fatty liver disease andquantification of liver fat using a new quantitative ultrasound technique

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 7, 2015, Pages 1337-1345.e6

  Lin, Steven C ^a   Heba, Elhamy ^a   Wolfson, Tanya ^b   Ang, Brandon ^a   Gamst, Anthony ^b   Han, Aiguo ^c   Erdman, John W ^d   O'Brien, William D ^c   Andre, Michael P ^a,e   Sirlin, Claude B ^a   Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Illinois at Urbana Champaign   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

AUC; Biomarker; Chronic liver disease; Diagnostic; Hepatic steatosis; Magnetic resonance imaging; Nonalcoholic steatohepatitis

Indexed keywords

FAT;

ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HUMAN; LIPID LIVER LEVEL; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; AGED; ANIMAL; CALIFORNIA; COMPARATIVE STUDY; EVALUATION STUDY; FATTY LIVER; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CALIFORNIA; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; ULTRASONOGRAPHY;

EID: 84931574623     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.027     Document Type: Article

References (40)

1. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
2. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
3. Targher G., Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191:235-240.
4. Zarrinpar A., Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 36:909-921.
5. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013, 10:330-344.
6. Loomba R., Abraham M., Unalp A., et al. Association betweendiabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
7. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
8. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
9. Williamson R.M., Price J.F., Glancy S., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011, 34:1139-1144.
10. Stinton L.M., Loomba R. Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2014, 60:5-13.
11. Schwenzer N.F., Springer F., Schraml C., et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. JHepatol 2009, 51:433-445.
12. Festi D., Schiumerini R., Marzi L., et al. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013, 37:392-400.
13. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
14. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. JHepatol 2013, 59:859-871.
15. Ghoshal G., Lavarello R.J., Kemmerer J.P., et al. Exvivo study of quantitative ultrasound parameters in fatty rabbit livers. Ultrasound Med Biol 2012, 38:2238-2248.
16. Sasso M., Miette V., Sandrin L., et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012, 36:13-20.
17. Springer F., Machann J., Claussen C.D., et al. Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol 2010, 16:1560-1566.
18. Permutt Z., Le T.A., Peterson M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012, 36:22-29.
19. Tang A., Tan J., Sun M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013, 267:422-431.
20. Ratziu V., Bellentani S., Cortez-Pinto H., et al. Aposition statement on NAFLD/NASH based on the EASL 2009 special conference. JHepatol 2010, 53:372-384.
21. Reeder S.B., Cruite I., Hamilton G., et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. JMagn Reson Imaging 2011, 34:729-749.
22. Weijers G., Starke A., Thijssen J.M., et al. Transcutaneous vs. intraoperative quantitative ultrasound for staging bovine hepatic steatosis. Ultrasound Med Biol 2012, 38:1404-1413.
23. Gaitini D., Baruch Y., Ghersin E., et al. Feasibility study of ultrasonic fatty liver biopsy: texture vs. attenuation and backscatter. Ultrasound Med Biol 2004, 30:1321-1327.
24. O'Brien R.T., Zagzebski J.A., Lu Z.F., et al. Measurement of acoustic backscatter and attenuation in the liver of dogs with experimentally induced steroid hepatopathy. Am J Vet Res 1996, 57:1690-1694.
25. Lu Z.F., Zagzebski J.A., O'Brien R.T., et al. Ultrasound attenuation and backscatter in the liver during prednisone administration. Ultrasound Med Biol 1997, 23:1-8.
26. Yao L.X., Zagzebski J.A., Madsen E.L. Backscatter coefficient measurements using a reference phantom to extract depth-dependent instrumentation factors. Ultrason Imaging 1990, 12:58-70.
27. Nam K., Rosado-Mendez I.M., Wirtzfeld L.A., et al. Comparison of ultrasound attenuation and backscatter estimates in layered tissue-mimicking phantoms among three clinical scanners. Ultrason Imaging 2012, 34:209-221.
28. Le T.A., Chen J., Changchien C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932.
29. Noureddin M., Lam J., Peterson M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58:1930-1940.
30. Brunke S.S., Insana M.F., Dahl J.J., et al. An ultrasound research interface for a clinical system. IEEE Trans Ultrason Ferroelectr Freq Control 2007, 54:198-210.
31. Noureddin M., Loomba R. Nonalcoholic fatty liver disease: indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis 2012, 1:104-107.
32. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
33. Taylor K.J., Gorelick F.S., Rosenfield A.T., et al. Ultrasonography of alcoholic liver disease with histological correlation. Radiology 1981, 141:157-161.
34. Joseph A.E., Saverymuttu S.H., al-Sam S., et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
35. Saverymuttu S.H., Joseph A.E., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986, 292:13-15.
36. Hamaguchi M., Kojima T., Itoh Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102:2708-2715.
37. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
38. Reeder S.B., Hu H.H., Sirlin C.B. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. JMagn Reson Imaging 2012, 36:1011-1014.
39. Patel N.S., Peterson M.R., Brenner D.A., et al. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 37:630-639.
40. Idilman I.S., Aniktar H., Idilman R., et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013, 267:767-775.